Early Promise From Axovant’s Parkinson’s Gene Therapy
But Investors Spooked By Incomplete Results
Executive Summary
Gene therapy shows promise in treating movement disorders in 4 patients, matching longer-term results from rivals Neurocrine Biosciences and Voyager Therapeutics.